MIRA Pharmaceuticals Inc
mirapharmaceuticals.comWhat Do They Do?
Develops oral drug candidates targeting pain, neurological and neuropsychiatric conditions, and metabolic and addiction-related disorders.
10-K for FY2025, filed Mar 31, 2026MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA, the “Company”, “we”, “us”) is a clinical-stage pharmaceutical development company advancing a…View ↗
Ketamir-2 is a patent-pending, orally bioavailable NMDA receptor modulator being developed for neuropathic pain, with an initial focus on…View ↗
MIRA-55 is a novel oral cannabinoid analog in preclinical development for inflammatory pain and central nervous system–related conditions…View ↗
SKNY-1 is a preclinical-stage oral therapeutic candidate designed to modulate CB1 and CB2 receptor signaling and selectively inhibit…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
-
Jul 31, 2026
Nasdaq notified MIRA of a minimum bid-price deficiency
The shares continued trading while MIRA had 180 calendar days to regain compliance.
Sources
8-K, filed Jul 31, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until January 25…View ↗
-
Jun 8, 2026
MIRA appointed a fractional CFO after its CFO departed
Alan Weichselbaum left, and Andriy Mushak became the fractional chief financial officer.
Sources
8-K, filed Jun 8, 2026
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the…View ↗
Loading...
